Basilea Pharmaceutica AG BSLN
SIX · Switzerland · Health Technology
CHF 67.80-2.10 (-3.00%)
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its partner Asahi Kasei Therapeutics Corp. started a phase 2 clinical study in Japan with the antifungal Cresemba® (isavuconazole) for pediatric patients at risk of deep mycoses. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very
Basilea Pharmaceutica (SWX:BSLN) is back in focus after reporting half year 2026 results on 18 August, with higher revenue and net income, and issuing upgraded full year revenue and operating profit guidance. See our latest analysis for Basilea Pharmaceutica. The earnings beat and raised guidance have coincided with a sharp pickup in momentum for Basilea Pharmaceutica, with a 30 day share price return of 25.19% and a 1 year total shareholder return of 38.11%. If this kind of move has your...
Strong first-half performance driven by Cresemba royalties and non-dilutive funding, with pipeline progress on track.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.